Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Eli Lilly CEO David Ricks reveals that developing a new drug costs around $4 billion before marketing. In an exclusive ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, ...

Now, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has launched its own ...

Unlike the US, Europe or other developed markets, Mounjaro will have to be purchased out-of-pocket in India, as obesity is ...

Eli Lilly's CEO David Ricks discusses the launch of diabetes and anti-obesity drugs Mounjaro and Zepbound, focusing on expanding access in emerging markets. He highlights new weight-loss drugs and ...

With approximately 101 million individuals living with diabetes, increasing access to insulin and advanced treatments is ...

In a nation where the battle against the stomach bulge is as intense as the love for butter parathas, a new player has ...

Zerodha CEO Nithin Kamath described weight-loss drugs Ozempic and Mounjaro as near 'miracle drugs,' highlighting their ...